Seeking Alpha

Pharmacyclics' (PCYC +5.2%) ibrutinib has substantial commercial potential, says Needham. After...

Pharmacyclics' (PCYC +5.2%) ibrutinib has substantial commercial potential, says Needham. After reviewing the data, Needham sees PCYC and collaborator Johnson & Johnson (JNJ -0.1%) being in a strong position given the drug's potential as both a front-line and relapsed or refractory agent. The firm believes a single-agent Phase 3 trial in front-line elderly chronic lymphocytic leukemia cases may be possible by the end of this year.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|